M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 12.04 PLN 1.35% Market Closed
Market Cap: 194.6m PLN
Have any thoughts about
Mabion SA?
Write Note

Operating Margin
Mabion SA

27.8%
Current
-220%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.8%
=
Operating Profit
30.8m
/
Revenue
110.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
PL
Mabion SA
WSE:MAB
194.6m PLN
28%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.8B EUR
-22%
Country PL
Market Cap 194.6m PLN
Operating Margin
28%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 116.2B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 81.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.8B EUR
Operating Margin
-22%
No Stocks Found

Mabion SA
Glance View

Market Cap
194.6m PLN
Industry
Biotechnology

Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

MAB Intrinsic Value
13.91 PLN
Undervaluation 13%
Intrinsic Value
Price
M

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.8%
=
Operating Profit
30.8m
/
Revenue
110.8m
What is the Operating Margin of Mabion SA?

Based on Mabion SA's most recent financial statements, the company has Operating Margin of 27.8%.